Eli Lilly could be the next stock to cross $1 trillion, says Jim Cramer

Eli Lilly could be the next stock to cross $1 trillion, says Jim Cramer

Jim Cramer on what could be the next $1 trillion stockПодробнее

Jim Cramer on what could be the next $1 trillion stock

Eli Lilly's weight-loss drug could be the best selling drug of all time, says Jim CramerПодробнее

Eli Lilly's weight-loss drug could be the best selling drug of all time, says Jim Cramer

Jim Cramer looks ahead to next week's market game planПодробнее

Jim Cramer looks ahead to next week's market game plan

Celsius expects big shelf space gains, possibly the best in its history, says Jim CramerПодробнее

Celsius expects big shelf space gains, possibly the best in its history, says Jim Cramer

We stuck with Eli Lilly because we did the homework, says Jim CramerПодробнее

We stuck with Eli Lilly because we did the homework, says Jim Cramer

Cramer’s Mad Dash: Eli LillyПодробнее

Cramer’s Mad Dash: Eli Lilly

Eli Lilly could have the 'biggest drug in history' in its pipeline, says Jim CramerПодробнее

Eli Lilly could have the 'biggest drug in history' in its pipeline, says Jim Cramer

Lightning Round: Buy Eli Lilly instead of Novo, says Jim CramerПодробнее

Lightning Round: Buy Eli Lilly instead of Novo, says Jim Cramer

Jim Cramer on the huge potential for Eli Lilly's answer to Ozempic #ShortsПодробнее

Jim Cramer on the huge potential for Eli Lilly's answer to Ozempic #Shorts

Cramer’s Mad Dash: Eli LillyПодробнее

Cramer’s Mad Dash: Eli Lilly

Recursion Pharmaceuticals CEO Chris Gibson goes one-on-one with Jim CramerПодробнее

Recursion Pharmaceuticals CEO Chris Gibson goes one-on-one with Jim Cramer

Mark Zuckerberg reacts to Elon Musk possibly buying Twitter #shortsПодробнее

Mark Zuckerberg reacts to Elon Musk possibly buying Twitter #shorts

Jim Cramer says there's a buying opportunity in this pharmaceutical companyПодробнее

Jim Cramer says there's a buying opportunity in this pharmaceutical company

The decline in Eli Lilly can be attributed to 'authentic stupidity', says Jim CramerПодробнее

The decline in Eli Lilly can be attributed to 'authentic stupidity', says Jim Cramer

Eli Lilly's experimental obesity drug could be 'revolutionary,' says Jim CramerПодробнее

Eli Lilly's experimental obesity drug could be 'revolutionary,' says Jim Cramer

Cramer’s Stop Trading: Eli LillyПодробнее

Cramer’s Stop Trading: Eli Lilly

Jim Cramer: I remain very positive on Eli Lilly as the drug stock of the yearПодробнее

Jim Cramer: I remain very positive on Eli Lilly as the drug stock of the year

You had to be in Eli Lilly before we got its results, not after, says Jim CramerПодробнее

You had to be in Eli Lilly before we got its results, not after, says Jim Cramer

Cramer’s Stop Trading: Eli LillyПодробнее

Cramer’s Stop Trading: Eli Lilly

Актуальное